{"id":"varicella-vaccine-live","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"10-15","effect":"Fever"},{"rate":"3-5","effect":"Varicella-like rash (vaccine strain)"},{"rate":"1-2","effect":"Myalgia"}]},"_chembl":null,"_dailymed":{"setId":"73eae9fc-507b-4c9c-883d-63eb2e3cc6f6","title":"PROQUAD (MEASLES, MUMPS, RUBELLA AND VARICELLA VIRUS VACCINE LIVE) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened live strain of varicella-zoster virus (VZV) that replicates in the body without causing disease in immunocompetent individuals. This replication triggers both humoral (antibody) and cellular immune responses, providing protection against natural varicella infection and reducing the risk of herpes zoster (shingles) later in life.","oneSentence":"A live attenuated varicella-zoster virus vaccine that stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:17.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox) in susceptible individuals"},{"name":"Prevention of herpes zoster (shingles) in vaccinated individuals"}]},"trialDetails":[{"nctId":"NCT07473427","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-05-01","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07475000","phase":"PHASE3","title":"Second Dose of Varicella Vaccine in Healthy Children","status":"RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-01-28","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07415252","phase":"PHASE3","title":"SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-06-05","conditions":"Varicella (Chickenpox)","enrollment":780},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT06891872","phase":"PHASE4","title":"Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-05","conditions":"Varicella (chickenpox), MMR Vaccine, DTaP Vaccine","enrollment":720},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT06801509","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-15","conditions":"Herpes Zoster","enrollment":540},{"nctId":"NCT05095701","phase":"PHASE4","title":"An Immunity Persistence Study of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-12-18","conditions":"Varicella","enrollment":703},{"nctId":"NCT06314724","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-02-29","conditions":"Varicella","enrollment":642},{"nctId":"NCT06484686","phase":"PHASE4","title":"An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Varicella","enrollment":414},{"nctId":"NCT06614816","phase":"PHASE3","title":"Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-02-10","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT06592456","phase":"PHASE3","title":"A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-07-21","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT04089930","phase":"","title":"Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2020-06-01","conditions":"Lupus Erythematosus","enrollment":68},{"nctId":"NCT05158777","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-02-13","conditions":"Varicella","enrollment":2480},{"nctId":"NCT04072497","phase":"PHASE1, PHASE2","title":"A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-20","conditions":"Herpes Zoster","enrollment":522},{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":54},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT05952505","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2023-08","conditions":"SARS-CoV-2 Infection, Varicella, Measles","enrollment":540},{"nctId":"NCT04384016","phase":"PHASE4","title":"Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2021-04-17","conditions":"Chickenpox","enrollment":201},{"nctId":"NCT05839301","phase":"PHASE3","title":"A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2023-04-27","conditions":"Varicella","enrollment":1200},{"nctId":"NCT05669625","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2022-12-26","conditions":"Varicella","enrollment":12440},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05664152","phase":"NA","title":"An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years","status":"UNKNOWN","sponsor":"GC Biopharma Corp","startDate":"2023-02","conditions":"Varicella Zoster Virus Infection","enrollment":250},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT01600079","phase":"","title":"ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-15","conditions":"Herpes Zoster, Shingles","enrollment":1505647},{"nctId":"NCT00940940","phase":"PHASE4","title":"Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-10","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05150392","phase":"PHASE3","title":"An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2018-07-11","conditions":"Varicella","enrollment":1193},{"nctId":"NCT04334577","phase":"PHASE3","title":"Study on Efficacy of Attenuated Zoster Vaccine, Live","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2020-04-20","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT02538341","phase":"PHASE2","title":"Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-05","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis","enrollment":617},{"nctId":"NCT00851786","phase":"PHASE2","title":"Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04-29","conditions":"Herpes Zoster, HIV Infections","enrollment":395},{"nctId":"NCT00001125","phase":"PHASE1","title":"Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Chickenpox","enrollment":60},{"nctId":"NCT00000837","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":127},{"nctId":"NCT00213304","phase":"PHASE3","title":"The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"1999-06","conditions":"Organ Transplantation, Immunosuppression","enrollment":21},{"nctId":"NCT00681031","phase":"PHASE4","title":"Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-14","conditions":"Herpes Zoster","enrollment":96},{"nctId":"NCT01262300","phase":"PHASE1","title":"Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":"Immunosenescence, Shingles","enrollment":33},{"nctId":"NCT03843632","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-01","conditions":"Varicella","enrollment":150},{"nctId":"NCT03314103","phase":"PHASE3","title":"Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-10-06","conditions":"Herpes Zoster","enrollment":30000},{"nctId":"NCT03239873","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-17","conditions":"Varicella","enrollment":600},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT03493776","phase":"PHASE4","title":"Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation","status":"UNKNOWN","sponsor":"Deepali Kumar","startDate":"2018-04-15","conditions":"Varicella Zoster Vaccine","enrollment":50},{"nctId":"NCT03685682","phase":"PHASE3","title":"Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-05-25","conditions":"Varicella Zoster Vaccine","enrollment":23},{"nctId":"NCT02114333","phase":"PHASE1","title":"Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-05","conditions":"Shingles, Herpes Zoster","enrollment":160},{"nctId":"NCT03016884","phase":"PHASE4","title":"Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-01","conditions":"Herpes Zoster","enrollment":87},{"nctId":"NCT02590068","phase":"NA","title":"Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2015-12","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02624375","phase":"PHASE4","title":"Immune Response to Shingles Vaccination","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-02","conditions":"Shingles","enrollment":10},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT00092430","phase":"PHASE3","title":"Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09-26","conditions":"Measles, Mumps, Rubella","enrollment":1200},{"nctId":"NCT02329457","phase":"PHASE2, PHASE3","title":"VZV Vaccine for Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2014-12","conditions":"Varicella Zoster Infection","enrollment":100},{"nctId":"NCT00226499","phase":"PHASE3","title":"Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-01","conditions":"Varicella, Chickenpox Vaccines","enrollment":5803},{"nctId":"NCT03114943","phase":"PHASE3","title":"Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2016-07-14","conditions":"Varicella","enrollment":516},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT00326183","phase":"PHASE4","title":"Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-26","conditions":"Hepatitis A, Measles, Mumps","enrollment":1800},{"nctId":"NCT00496327","phase":"PHASE3","title":"Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06-22","conditions":"Varicella","enrollment":100},{"nctId":"NCT00561080","phase":"PHASE3","title":"Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-26","conditions":"Prevention of : Herpes-Zoster","enrollment":759},{"nctId":"NCT00792623","phase":"PHASE2","title":"Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-08","conditions":"Varicella","enrollment":45},{"nctId":"NCT02519855","phase":"PHASE3","title":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-11","conditions":"Herpes Zoster","enrollment":882},{"nctId":"NCT02062502","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-07","conditions":"Varicella","enrollment":611},{"nctId":"NCT01527370","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-31","conditions":"Herpes Zoster, Shingles","enrollment":250},{"nctId":"NCT01506193","phase":"PHASE3","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02-06","conditions":"Rubella, Varicella, Measles","enrollment":716},{"nctId":"NCT00402831","phase":"PHASE3","title":"ProQuad® Intramuscular vs Subcutaneous","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Measles, Mumps, Rubella","enrollment":405},{"nctId":"NCT03555071","phase":"PHASE3","title":"A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2014-04-07","conditions":"Varicella","enrollment":1197},{"nctId":"NCT01573182","phase":"PHASE2","title":"Herpes Zoster Vaccine for Bone Marrow Transplant Donors","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2012-04","conditions":"Herpes Zoster","enrollment":8},{"nctId":"NCT02692066","phase":"","title":"Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2016-04","conditions":"Varicella, Transplants","enrollment":""},{"nctId":"NCT02444936","phase":"PHASE4","title":"ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors","status":"UNKNOWN","sponsor":"Louis Stokes VA Medical Center","startDate":"2015-05-01","conditions":"Shingles","enrollment":22},{"nctId":"NCT00432042","phase":"PHASE3","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-12","conditions":"Varicella, Measles, Mumps","enrollment":955},{"nctId":"NCT00322049","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-02","conditions":"Dengue","enrollment":51},{"nctId":"NCT02983656","phase":"","title":"Analysis on AEFI Surveillance Data for Live Attenuated Varicella Vaccine","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2016-11","conditions":"Varicocele","enrollment":394},{"nctId":"NCT02965404","phase":"PHASE1","title":"A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2016-04","conditions":"Varicella","enrollment":270},{"nctId":"NCT02981836","phase":"PHASE3","title":"A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2016-08","conditions":"Varicella","enrollment":5997},{"nctId":"NCT00560755","phase":"PHASE3","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-24","conditions":"Measles, Mumps, Rubella","enrollment":3388},{"nctId":"NCT02958345","phase":"PHASE4","title":"Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™","status":"COMPLETED","sponsor":"Tulane University","startDate":"2013-06","conditions":"Herpes Zoster, Fibrosis","enrollment":28},{"nctId":"NCT02408159","phase":"PHASE4","title":"Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy","status":"TERMINATED","sponsor":"Innovaderm Research Inc.","startDate":"2016-06","conditions":"Psoriasis","enrollment":3},{"nctId":"NCT03121638","phase":"PHASE1","title":"Safety Study of NBP608 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2012-11","conditions":"Varicella Zoster, Immunization; Infection","enrollment":150},{"nctId":"NCT03120364","phase":"PHASE3","title":"Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-09-09","conditions":"Herpes Zoster","enrollment":824},{"nctId":"NCT03116594","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-01-03","conditions":"Herpes Zoster","enrollment":675},{"nctId":"NCT03114982","phase":"PHASE2","title":"The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2016-05","conditions":"Varicella","enrollment":152},{"nctId":"NCT00550745","phase":"PHASE4","title":"ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Herpes Zoster","enrollment":11999},{"nctId":"NCT00822237","phase":"PHASE3","title":"Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Varicella","enrollment":598},{"nctId":"NCT01505647","phase":"PHASE3","title":"Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-04","conditions":"Herpes Zoster, Shingles","enrollment":498},{"nctId":"NCT00546819","phase":"PHASE2","title":"ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Herpes Zoster","enrollment":309},{"nctId":"NCT01245751","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04","conditions":"Herpes Zoster, Varicella-zoster Vaccine","enrollment":600},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Herpes Zoster, Pneumococcal Infection","enrollment":473},{"nctId":"NCT00534248","phase":"PHASE3","title":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Shingles","enrollment":22439},{"nctId":"NCT01556451","phase":"PHASE4","title":"ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-04","conditions":"Herpes Zoster, Shingles","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VARIPED®","ONVARA®"],"phase":"marketed","status":"active","brandName":"Varicella vaccine live","genericName":"Varicella vaccine live","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"A live attenuated varicella-zoster virus vaccine that stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox). Used for Prevention of varicella (chickenpox) in susceptible individuals, Prevention of herpes zoster (shingles) in vaccinated individuals.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}